Monitor for final IPO pricing and initial trading volume. Key catalysts: completion of the SPA-guided Tarsier-04 Phase 3 trial (expected to initiate Q3 2026), FDA interactions, and partner discussions. High cash burn and going concern risk make post-IPO dilution likely.
Executive Summary
Tarsier Pharma Ltd., an Israeli late clinical-stage biopharmaceutical company focused on inflammatory ocular diseases, files Amendment No. 1 to its F-1 registration statement for an initial public offering of 5,000,000 ordinary shares at an estimated price range of $8.00 to $10.00 per share. Net proceeds of approximately $41.0 million (midpoint) will primarily fund the Phase 3 pivotal trial of lead candidate TRS01 for non-infectious anterior uveitis and uveitic glaucoma, NDA preparation, and TRS02 development. The company has a history of losses ($5.1M in 2025), a going concern risk, and its prior Phase 3 trial missed the primary endpoint, though an FDA SPA agreement supports a new trial design with IOP as the primary endpoint.
Key Financial Metrics
Key Facts
- Offering: 5,000,000 ordinary shares (plus 750,000 over-allotment) at $8.00-$10.00 per share; listing on NYSE under ticker TARX.
- Net proceeds estimated at $41.0M (midpoint) to fund TRS01 Phase 3 program ($25M), NDA preparation ($6M), TRS02 R&D ($4M), CEO loan/deferred comp repayment ($0.678M), and working capital.
- Net loss of $5.07M in 2025; accumulated deficit of $26.93M; cash of $1.999M as of Dec 31, 2025; going concern doubt stated.
- Lead candidate TRS01 (dazdotuftide eye drops) targets non-infectious anterior uveitis and uveitic glaucoma; prior Phase 3 trial missed primary endpoint but FDA SPA agreed on new pivotal trial with IOP safety as primary endpoint.
- Second candidate TRS02 (intravitreal slow-release) is in preclinical development for posterior uveitis, DME, NPDR, and dry-AMD.
- Underwriter: Konik Capital Partners (a division of T.R. Winston & Co.); lock-up period of 180 days for insiders.
Financial Impact
IPO expected to raise ~$41M net (midpoint); company has no revenue and $5.1M annual net loss.
Risk Factors
- Prior Phase 3 trial (TRS4Vision) failed primary endpoint; new trial design changes endpoint to IOP safety, which may not guarantee approval.
- Going concern risk persists even after IPO; additional capital needed to complete development.
- No products approved; no revenue; history of losses.
- Dependence on lead product candidate TRS01; pipeline concentration risk.
- Israeli company with geopolitical risk and currency exposure.
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001213900-26-058235 |
| Document: ea027016608ex3-1.htm | 0001213900-26-058235 |
| Document: ea027016608ex3-2.htm | 0001213900-26-058235 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 19w ago | F-1/A | — | awaiting T+20 | — | — |
Jun 8, 2026 20w ago | F-1/A | — | awaiting T+20 | — | — |
May 18, 2026 23w ago | F-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers